Posted: 06/02/2025 07:17 am
Aytu BioPharma, Inc. (NASDAQ: AYTU), a company strategically focused on commercializing novel therapeutics, has shown a dynamic approach to its executive compensation over the past few years, reflecting its evolving financial landscape and strategic goals. Recent compensation data reveals how Aytu has navigated its financial trajectory, complemented by significant operational achievements.
In 2024, the former Chief Financial Officer and Corporate Secretary/Treasurer received a total compensation of $584,669, which included a base salary of $427,450, an option award of $20,435, and $136,784 from incentive plan compensation. This represents a strategic focus on performance-based incentives despite the challenging market conditions, as evidenced by the complete absence of a bonus and stock awards for that fiscal year¹.
Looking back at 2023, Greg Pyszczymuka received $540,046 in total compensation. His package consisted of a $375,000 salary and a notable $150,000 bonus, illustrating a more aggressive reward system to acknowledge achievements within the company or industry at that time². This structure differed significantly from 2024, highlighting a shift in approach towards managing executive compensations.
In 2021, the former CFO who resigned in December had an impressive compensation package totaling $782,881. This included $455,947 in stock awards, which were likely leveraged as a retention strategy or as a reward for prior performance amid transitional phases within the company³. Meanwhile, in 2020, the Chief Executive Officer Joshua R. Disbrow, at the helm since 2012, received a total compensation of $1,585,450, heavily weighted with a $652,500 stock award and $185,000 bonus, indicating robust recognition of his leadership during a turbulent period marked by heightened uncertainty within the pharmaceutical sector⁴.
Financial reporting from Aytu highlights substantial growth in certain segments, marking a successful pivot in some of its strategic areas. For instance, the company recently reported a net income of $4.0 million in its Fiscal 2025 third quarter, with a notable increase in total net revenue by 32% year-over-year⁵. This income boost follows earlier reports from its second quarter in 2025 demonstrating sequential growth in its pediatric portfolio⁶. These gains are likely influenced by the leadership and their incentivized goals to achieve higher performance outputs, as suggested by their shifting compensation policies over recent years.
Currently, Aytu BioPharma’s market activities reflect on the NASDAQ with a stock price of $1.78, although it recently experienced a decrease of 2.73%⁷. Despite fluctuations, the company’s strategic shifts in executive compensation point to a commitment to aligning leadership incentives with the overarching growth and stabilization strategies being implemented at Aytu.
These compensation patterns appear consistent with Aytu's objective to fortify its market position while rewarding effective leadership that aligns with their innovative pharmaceutical advancements and overall financial health.
1. SEC Filing, 2024 Compensation [Link](https://www.sec.gov/Archives/edgar/data/1385818/000143774925009836/0001437749-25-009836-index.htm)
2. SEC Filing, 2023 Compensation [Link](https://www.sec.gov/Archives/edgar/data/1385818/000143774924016003/0001437749-24-016003-index.htm)
3. SEC Filing, 2021 Compensation [Link](https://www.sec.gov/Archives/edgar/data/1385818/000155837023005628/0001558370-23-005628-index.htm)
4. SEC Filing, 2020 Compensation [Link](https://www.sec.gov/Archives/edgar/data/1385818/000110465922043439/0001104659-22-043439-index.htm)
5. AccessNewswire, Fiscal 2025 Third Quarter Results [Link](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-reports-fiscal-2025-third-quarter-operational-and-fina-1027225)
6. AccessNewswire, Fiscal 2025 Second Quarter Results [Link](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-reports-fiscal-2025-second-quarter-operational-and-fina-983506)
7. Current Stock Price & Data [NASDAQ Data](https://finance.yahoo.com/quote/AYTU)
